Few companies in the micro cap arena have garnered as much attention as Organovo (ONVO). Since its reverse merger in February 2012, thirty-nine articles have been published on Seeking Alpha. Today, almost 13,000 SA subscribers receive email alerts on the company. In a list of biotech stocks with market caps between $500M and $1B with a relative strength rating of at least 80 (per IBD), ONVO is the most-followed firm by a factor of four.
Anyone who is even casually familiar with the company knows that its long-term value proposition in regenerative medicine, tissue engineering in particular, is the reason why. What's not to like? The ability to print fully functioning replacement organs and tissues is such a...
Only subscribers can access this article, which is part of the PRO research library covering 3,609 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: